AbbVie’s immunology blockbusters make up for Humira sales drop in Q3

AbbVie is lifting its profit outlook and full-year 2024 guidance as its immunology blockbusters Skyrizi and Rinvoq beat quarterly revenue estimates, according to the company’s third-quarter filing. Global Skyrizi net revenues ...